Trial Profile
A Single-Center study of oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism in patients with Active Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jul 2018
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Cancer; Venous thromboembolism
- Focus Therapeutic Use
- 21 Jul 2018 New trial record